Summary of Bill: Biodefense Diplomacy Enhancement Act (H.R. 7653, 119th Congress)

Purpose and overarching goal
- The Biodefense Diplomacy Enhancement Act seeks to strengthen United States diplomacy and international cooperation on biotechnology, biosecurity, and biodefense.
- It focuses on engaging allies and partners—especially within NATO and other major non-NATO allies—to improve policy development, interoperability, export controls, and collaborative efforts to prevent, detect, and respond to biological threats.

Key provisions and changes

1) Enhancement of diplomatic engagement (Section 2)
- The Secretary of State is directed to advance U.S. foreign policy goals to improve international cooperation in biodefense, biosecurity, and biotechnology with allies and partners.

2) NATO-focused policy development ( subsection b )
- Aimed at strengthening NATO-related biodefense efforts, including:
- Prioritizing NATO policy development in biodefense (biotech, biosurveillance, countermeasures).
- Identifying and addressing gaps in NATO planning and actions related to biodefense and biotechnology.
- Considering revisions or amendments to the NATO CBRN (Chemical, Biological, Radiological, and Nuclear) Defence Policy to bolster bio-defense.
- Coordinating with NATO members to implement relevant measures.
- Improving interoperability, resilience, detection, emergency response, and recovery capabilities against weaponized biological threats.
- Exploring expanded NATO capabilities for research, development, and deployment of biotechnology for international security.
- Encouraging NATO member adherence to high safety and security standards in biological research.

3) Cooperation with U.S. allies and partners ( subsection c )
- Broader international cooperation in biotechnology, biosecurity, and biodefense, including:
- Exploring cooperation with major non-NATO allies in biotech and biosecurity.
- Coordinating export control policies on biotechnology, including dual-use items that could enable bioweapons development.
- Promoting safety and security standards in biological research among U.S. allies and partners.
- Collaborating to enforce the Biological Weapons Convention (BWC).

4) Strategic planning and guidance ( subsection d )
- Two integrated strategies to be developed:
- NATO Biodefense Strategy: Assess current U.S.-NATO cooperation, identify gaps in biotech and biodefense, recommend actions, and review interagency cooperation.
- International Biotechnology, Biosecurity, and Biodefense Cooperation Strategy: Proposals for commitments with allies and partners, assessment of export-control coordination with regimes like Wassenaar and Australia Group, and overview of NADR (nonproliferation, anti-terrorism, demining) programs to strengthen international biosecurity cooperation and export-control effectiveness.

5) Limitations ( subsection d(3) )
- Strategies are limited to addressing threats posed by biological agents and toxins as defined by law (18 U.S.C. § 178).

6) Reporting and congressional oversight (sections e and f)
- A comprehensive report detailing the NATO Biodefense Strategy and the International Cooperation Strategy must be submitted to Congress within 270 days of enactment. The report may be unclassified with a classified annex.
- A congressional briefing is required within 90 days of enactment to update on strategic developments and global biosecurity matters.

7) Definitions (section g)
- Provides standardized definitions for terms including:
- Biodefense, biological threat, biosecurity, biosurveillance, biotechnology.
- Countries that are major non-NATO allies.
- Relevant processes and terms used in the bill’s context.

Administrative and timeline notes
- Introduced February 23, 2026; referred to the House Committee on Foreign Affairs, with a later mark-up and reporting action.
- Action history shows a committee report and approval in March 2026 (46-0 vote in committee).

Who is affected
- U.S. Department of State (primarily the Under Secretary for Arms Control and International Security, in coordination with the Under Secretary for Political Affairs and the U.S. Permanent Representative to NATO).
- NATO and its member states, and major non-NATO ally countries with whom the U.S. engages on biotechnology and biodefense.
- Export-control policymakers and agencies coordinating with allied nations on biotech-related dual-use items.
- Congress, which would receive strategic reports and briefings.

Potential impact and significance
- The bill would elevate and formalize U.S. diplomacy around biodefense and biotechnology with a focus on NATO coordination and international export controls.
- It could lead to new or revised NATO policy directions, expanded multinational cooperation on biosurveillance and countermeasures, and greater alignment of safety and security standards in biological research among allies.
- The NADR program and export-control coordination could see enhanced utilization to address biosecurity threats, potentially increasing international capacity-building and information-sharing.

Note: This summary reflects the bill text as introduced and its stated provisions; it does not interpret legislative likelihood or political considerations.